nodes	percent_of_prediction	percent_of_DWPC	metapath
Carvedilol—VEGFA—psoriasis	0.367	1	CbGaD
Carvedilol—CYP1A1—Clobetasol propionate—psoriasis	0.0611	0.195	CbGbCtD
Carvedilol—CYP1A1—Methoxsalen—psoriasis	0.0321	0.103	CbGbCtD
Carvedilol—CYP1A2—Clobetasol propionate—psoriasis	0.0273	0.0872	CbGbCtD
Carvedilol—CYP1A1—Cholecalciferol—psoriasis	0.0212	0.0679	CbGbCtD
Carvedilol—CYP1A2—Methoxsalen—psoriasis	0.0143	0.0458	CbGbCtD
Carvedilol—CYP2D6—Hydroxyurea—psoriasis	0.0129	0.0413	CbGbCtD
Carvedilol—CYP3A4—Calcitriol—psoriasis	0.00965	0.0309	CbGbCtD
Carvedilol—CYP1A1—Dexamethasone—psoriasis	0.00919	0.0294	CbGbCtD
Carvedilol—CYP2C9—Cholecalciferol—psoriasis	0.00855	0.0273	CbGbCtD
Carvedilol—CYP2D6—Cholecalciferol—psoriasis	0.00782	0.025	CbGbCtD
Carvedilol—CYP3A4—Methoxsalen—psoriasis	0.00751	0.024	CbGbCtD
Carvedilol—VCAM1—synovial membrane of synovial joint—psoriasis	0.00745	0.187	CbGeAlD
Carvedilol—ABCB1—Mycophenolate mofetil—psoriasis	0.0072	0.023	CbGbCtD
Carvedilol—CYP2E1—Dexamethasone—psoriasis	0.0071	0.0227	CbGbCtD
Carvedilol—ABCB1—Betamethasone—psoriasis	0.00617	0.0197	CbGbCtD
Carvedilol—ABCB1—Prednisolone—psoriasis	0.00609	0.0195	CbGbCtD
Carvedilol—ABCB1—Hydrocortisone—psoriasis	0.00578	0.0185	CbGbCtD
Carvedilol—ABCB1—Prednisone—psoriasis	0.00575	0.0184	CbGbCtD
Carvedilol—CYP2C9—Cyclosporine—psoriasis	0.00562	0.018	CbGbCtD
Carvedilol—ABCB1—Cyclosporine—psoriasis	0.00545	0.0174	CbGbCtD
Carvedilol—CYP2D6—Cyclosporine—psoriasis	0.00514	0.0164	CbGbCtD
Carvedilol—CYP3A4—Cholecalciferol—psoriasis	0.00497	0.0159	CbGbCtD
Carvedilol—GJA1—skin epidermis—psoriasis	0.00446	0.112	CbGeAlD
Carvedilol—CYP3A4—Triamcinolone—psoriasis	0.00431	0.0138	CbGbCtD
Carvedilol—CYP3A4—Mycophenolate mofetil—psoriasis	0.00431	0.0138	CbGbCtD
Carvedilol—SELE—endothelium—psoriasis	0.00377	0.0948	CbGeAlD
Carvedilol—CYP2C9—Dexamethasone—psoriasis	0.0037	0.0118	CbGbCtD
Carvedilol—CYP3A4—Betamethasone—psoriasis	0.0037	0.0118	CbGbCtD
Carvedilol—CYP3A4—Prednisolone—psoriasis	0.00365	0.0117	CbGbCtD
Carvedilol—ABCB1—Dexamethasone—psoriasis	0.00359	0.0115	CbGbCtD
Carvedilol—VCAM1—endothelium—psoriasis	0.00347	0.0872	CbGeAlD
Carvedilol—CYP3A4—Hydrocortisone—psoriasis	0.00346	0.0111	CbGbCtD
Carvedilol—CYP3A4—Prednisone—psoriasis	0.00345	0.011	CbGbCtD
Carvedilol—CYP2D6—Dexamethasone—psoriasis	0.00338	0.0108	CbGbCtD
Carvedilol—HIF1A—endothelium—psoriasis	0.00334	0.0839	CbGeAlD
Carvedilol—CYP3A4—Cyclosporine—psoriasis	0.00327	0.0104	CbGbCtD
Carvedilol—GJA1—endothelium—psoriasis	0.00324	0.0814	CbGeAlD
Carvedilol—ABCB1—Methotrexate—psoriasis	0.00289	0.00923	CbGbCtD
Carvedilol—CYP3A4—Dexamethasone—psoriasis	0.00215	0.00688	CbGbCtD
Carvedilol—SELE—skin of body—psoriasis	0.00161	0.0405	CbGeAlD
Carvedilol—HIF1A—skin of body—psoriasis	0.00142	0.0358	CbGeAlD
Carvedilol—GJA1—skin of body—psoriasis	0.00138	0.0348	CbGeAlD
Carvedilol—SELE—tendon—psoriasis	0.00123	0.0308	CbGeAlD
Carvedilol—VCAM1—tendon—psoriasis	0.00113	0.0284	CbGeAlD
Carvedilol—HIF1A—tendon—psoriasis	0.00108	0.0273	CbGeAlD
Carvedilol—CYP1A1—skin epidermis—psoriasis	0.00108	0.0271	CbGeAlD
Carvedilol—GJA1—tendon—psoriasis	0.00105	0.0265	CbGeAlD
Carvedilol—NDUFC2—tendon—psoriasis	0.000916	0.023	CbGeAlD
Carvedilol—VEGFA—tendon—psoriasis	0.000831	0.0209	CbGeAlD
Carvedilol—PTGS1—endothelium—psoriasis	0.000687	0.0173	CbGeAlD
Carvedilol—CYP1A1—skin of body—psoriasis	0.000334	0.0084	CbGeAlD
Carvedilol—GJA1—Rimexolone—Clobetasol propionate—psoriasis	0.000333	0.0831	CbGdCrCtD
Carvedilol—ADRA2C—tendon—psoriasis	0.000297	0.00747	CbGeAlD
Carvedilol—PTGS1—skin of body—psoriasis	0.000293	0.00738	CbGeAlD
Carvedilol—GJA1—Rimexolone—Fluocinonide—psoriasis	0.000267	0.0666	CbGdCrCtD
Carvedilol—GJA1—Rimexolone—Beclomethasone—psoriasis	0.000267	0.0666	CbGdCrCtD
Carvedilol—GJA1—Rimexolone—Fluocinolone Acetonide—psoriasis	0.000259	0.0647	CbGdCrCtD
Carvedilol—ADRA2A—tendon—psoriasis	0.000237	0.00596	CbGeAlD
Carvedilol—CYP2E1—tendon—psoriasis	0.000232	0.00583	CbGeAlD
Carvedilol—PTGS1—tendon—psoriasis	0.000223	0.00562	CbGeAlD
Carvedilol—GJA1—Cortisone acetate—Hydrocortisone—psoriasis	0.000195	0.0485	CbGdCrCtD
Carvedilol—GJA1—Cortisone acetate—Prednisone—psoriasis	0.000168	0.0418	CbGdCrCtD
Carvedilol—GJA1—Cortisone acetate—Prednisolone—psoriasis	0.000164	0.0408	CbGdCrCtD
Carvedilol—GJA1—Rimexolone—Hydrocortisone—psoriasis	0.000131	0.0327	CbGdCrCtD
Carvedilol—GJA1—Rimexolone—Dexamethasone—psoriasis	0.000122	0.0303	CbGdCrCtD
Carvedilol—GJA1—Rimexolone—Betamethasone—psoriasis	0.000122	0.0303	CbGdCrCtD
Carvedilol—GJA1—Rimexolone—Triamcinolone—psoriasis	0.000119	0.0296	CbGdCrCtD
Carvedilol—GJA1—Rimexolone—Prednisone—psoriasis	0.000113	0.0281	CbGdCrCtD
Carvedilol—GJA1—Rimexolone—Prednisolone—psoriasis	0.00011	0.0275	CbGdCrCtD
Carvedilol—GJA1—Progesterone—Hydrocortisone—psoriasis	9.53e-05	0.0238	CbGdCrCtD
Carvedilol—GJA1—Progesterone—Prednisolone—psoriasis	8.01e-05	0.02	CbGdCrCtD
Carvedilol—GJA1—Dexamethasone—Clobetasol propionate—psoriasis	7.55e-05	0.0188	CbGdCrCtD
Carvedilol—GJA1—Betamethasone—Clobetasol propionate—psoriasis	7.55e-05	0.0188	CbGdCrCtD
Carvedilol—VEGFA—Betamethasone—Clobetasol propionate—psoriasis	6.65e-05	0.0166	CbGdCrCtD
Carvedilol—VEGFA—Dexamethasone—Clobetasol propionate—psoriasis	6.65e-05	0.0166	CbGdCrCtD
Carvedilol—GJA1—Dexamethasone—Fluocinonide—psoriasis	6.04e-05	0.0151	CbGdCrCtD
Carvedilol—GJA1—Dexamethasone—Beclomethasone—psoriasis	6.04e-05	0.0151	CbGdCrCtD
Carvedilol—GJA1—Betamethasone—Fluocinonide—psoriasis	6.04e-05	0.0151	CbGdCrCtD
Carvedilol—GJA1—Betamethasone—Beclomethasone—psoriasis	6.04e-05	0.0151	CbGdCrCtD
Carvedilol—GJA1—Betamethasone—Fluocinolone Acetonide—psoriasis	5.87e-05	0.0146	CbGdCrCtD
Carvedilol—GJA1—Dexamethasone—Fluocinolone Acetonide—psoriasis	5.87e-05	0.0146	CbGdCrCtD
Carvedilol—VEGFA—Betamethasone—Fluocinonide—psoriasis	5.33e-05	0.0133	CbGdCrCtD
Carvedilol—VEGFA—Betamethasone—Beclomethasone—psoriasis	5.33e-05	0.0133	CbGdCrCtD
Carvedilol—VEGFA—Dexamethasone—Fluocinonide—psoriasis	5.33e-05	0.0133	CbGdCrCtD
Carvedilol—VEGFA—Dexamethasone—Beclomethasone—psoriasis	5.33e-05	0.0133	CbGdCrCtD
Carvedilol—VEGFA—Betamethasone—Fluocinolone Acetonide—psoriasis	5.18e-05	0.0129	CbGdCrCtD
Carvedilol—VEGFA—Dexamethasone—Fluocinolone Acetonide—psoriasis	5.18e-05	0.0129	CbGdCrCtD
Carvedilol—Gastrointestinal pain—Mycophenolate mofetil—psoriasis	4.74e-05	0.000305	CcSEcCtD
Carvedilol—Urticaria—Cyclosporine—psoriasis	4.72e-05	0.000304	CcSEcCtD
Carvedilol—Myalgia—Dexamethasone—psoriasis	4.7e-05	0.000303	CcSEcCtD
Carvedilol—Myalgia—Betamethasone—psoriasis	4.7e-05	0.000303	CcSEcCtD
Carvedilol—Body temperature increased—Cyclosporine—psoriasis	4.7e-05	0.000302	CcSEcCtD
Carvedilol—Abdominal pain—Cyclosporine—psoriasis	4.7e-05	0.000302	CcSEcCtD
Carvedilol—Vomiting—Mycophenolic acid—psoriasis	4.67e-05	0.0003	CcSEcCtD
Carvedilol—Discomfort—Betamethasone—psoriasis	4.65e-05	0.000299	CcSEcCtD
Carvedilol—Discomfort—Dexamethasone—psoriasis	4.65e-05	0.000299	CcSEcCtD
Carvedilol—Dyspepsia—Hydrocortisone—psoriasis	4.65e-05	0.000299	CcSEcCtD
Carvedilol—Haemoglobin—Methotrexate—psoriasis	4.64e-05	0.000299	CcSEcCtD
Carvedilol—Rash—Mycophenolic acid—psoriasis	4.63e-05	0.000298	CcSEcCtD
Carvedilol—Dermatitis—Mycophenolic acid—psoriasis	4.62e-05	0.000298	CcSEcCtD
Carvedilol—Pain—Prednisolone—psoriasis	4.62e-05	0.000297	CcSEcCtD
Carvedilol—Haemorrhage—Methotrexate—psoriasis	4.62e-05	0.000297	CcSEcCtD
Carvedilol—Urticaria—Mycophenolate mofetil—psoriasis	4.6e-05	0.000296	CcSEcCtD
Carvedilol—Headache—Mycophenolic acid—psoriasis	4.6e-05	0.000296	CcSEcCtD
Carvedilol—Decreased appetite—Hydrocortisone—psoriasis	4.59e-05	0.000295	CcSEcCtD
Carvedilol—Pharyngitis—Methotrexate—psoriasis	4.59e-05	0.000295	CcSEcCtD
Carvedilol—Abdominal pain—Mycophenolate mofetil—psoriasis	4.58e-05	0.000295	CcSEcCtD
Carvedilol—Body temperature increased—Mycophenolate mofetil—psoriasis	4.58e-05	0.000295	CcSEcCtD
Carvedilol—Urinary tract disorder—Methotrexate—psoriasis	4.56e-05	0.000294	CcSEcCtD
Carvedilol—Gastrointestinal disorder—Hydrocortisone—psoriasis	4.56e-05	0.000293	CcSEcCtD
Carvedilol—Fatigue—Hydrocortisone—psoriasis	4.55e-05	0.000293	CcSEcCtD
Carvedilol—Vision blurred—Prednisone—psoriasis	4.54e-05	0.000292	CcSEcCtD
Carvedilol—Urethral disorder—Methotrexate—psoriasis	4.53e-05	0.000291	CcSEcCtD
Carvedilol—Musculoskeletal discomfort—Triamcinolone—psoriasis	4.53e-05	0.000291	CcSEcCtD
Carvedilol—Pain—Hydrocortisone—psoriasis	4.51e-05	0.00029	CcSEcCtD
Carvedilol—Anaphylactic shock—Betamethasone—psoriasis	4.51e-05	0.00029	CcSEcCtD
Carvedilol—Oedema—Betamethasone—psoriasis	4.51e-05	0.00029	CcSEcCtD
Carvedilol—Oedema—Dexamethasone—psoriasis	4.51e-05	0.00029	CcSEcCtD
Carvedilol—Anaphylactic shock—Dexamethasone—psoriasis	4.51e-05	0.00029	CcSEcCtD
Carvedilol—Insomnia—Triamcinolone—psoriasis	4.5e-05	0.000289	CcSEcCtD
Carvedilol—Infection—Betamethasone—psoriasis	4.48e-05	0.000288	CcSEcCtD
Carvedilol—Infection—Dexamethasone—psoriasis	4.48e-05	0.000288	CcSEcCtD
Carvedilol—Ill-defined disorder—Prednisone—psoriasis	4.46e-05	0.000287	CcSEcCtD
Carvedilol—Paraesthesia—Triamcinolone—psoriasis	4.46e-05	0.000287	CcSEcCtD
Carvedilol—Feeling abnormal—Prednisolone—psoriasis	4.45e-05	0.000287	CcSEcCtD
Carvedilol—Visual impairment—Methotrexate—psoriasis	4.45e-05	0.000286	CcSEcCtD
Carvedilol—Anaemia—Prednisone—psoriasis	4.45e-05	0.000286	CcSEcCtD
Carvedilol—Shock—Dexamethasone—psoriasis	4.44e-05	0.000285	CcSEcCtD
Carvedilol—Shock—Betamethasone—psoriasis	4.44e-05	0.000285	CcSEcCtD
Carvedilol—Dyspnoea—Triamcinolone—psoriasis	4.43e-05	0.000285	CcSEcCtD
Carvedilol—Thrombocytopenia—Dexamethasone—psoriasis	4.42e-05	0.000284	CcSEcCtD
Carvedilol—Thrombocytopenia—Betamethasone—psoriasis	4.42e-05	0.000284	CcSEcCtD
Carvedilol—Tachycardia—Dexamethasone—psoriasis	4.4e-05	0.000283	CcSEcCtD
Carvedilol—Tachycardia—Betamethasone—psoriasis	4.4e-05	0.000283	CcSEcCtD
Carvedilol—Angioedema—Prednisone—psoriasis	4.4e-05	0.000283	CcSEcCtD
Carvedilol—Hypersensitivity—Cyclosporine—psoriasis	4.38e-05	0.000282	CcSEcCtD
Carvedilol—Dyspepsia—Triamcinolone—psoriasis	4.38e-05	0.000281	CcSEcCtD
Carvedilol—Erythema multiforme—Methotrexate—psoriasis	4.37e-05	0.000281	CcSEcCtD
Carvedilol—Nausea—Mycophenolic acid—psoriasis	4.36e-05	0.000281	CcSEcCtD
Carvedilol—Hyperhidrosis—Betamethasone—psoriasis	4.36e-05	0.00028	CcSEcCtD
Carvedilol—Hyperhidrosis—Dexamethasone—psoriasis	4.36e-05	0.00028	CcSEcCtD
Carvedilol—Feeling abnormal—Hydrocortisone—psoriasis	4.35e-05	0.00028	CcSEcCtD
Carvedilol—Malaise—Prednisone—psoriasis	4.34e-05	0.000279	CcSEcCtD
Carvedilol—Vertigo—Prednisone—psoriasis	4.32e-05	0.000278	CcSEcCtD
Carvedilol—Gastrointestinal pain—Hydrocortisone—psoriasis	4.32e-05	0.000278	CcSEcCtD
Carvedilol—Syncope—Prednisone—psoriasis	4.32e-05	0.000278	CcSEcCtD
Carvedilol—Tinnitus—Methotrexate—psoriasis	4.31e-05	0.000277	CcSEcCtD
Carvedilol—Anorexia—Betamethasone—psoriasis	4.3e-05	0.000277	CcSEcCtD
Carvedilol—Anorexia—Dexamethasone—psoriasis	4.3e-05	0.000277	CcSEcCtD
Carvedilol—Urticaria—Prednisolone—psoriasis	4.29e-05	0.000276	CcSEcCtD
Carvedilol—Fatigue—Triamcinolone—psoriasis	4.29e-05	0.000276	CcSEcCtD
Carvedilol—Hypersensitivity—Mycophenolate mofetil—psoriasis	4.27e-05	0.000275	CcSEcCtD
Carvedilol—Asthenia—Cyclosporine—psoriasis	4.26e-05	0.000274	CcSEcCtD
Carvedilol—Pain—Triamcinolone—psoriasis	4.25e-05	0.000273	CcSEcCtD
Carvedilol—Loss of consciousness—Prednisone—psoriasis	4.23e-05	0.000272	CcSEcCtD
Carvedilol—Hypotension—Dexamethasone—psoriasis	4.21e-05	0.000271	CcSEcCtD
Carvedilol—Hypotension—Betamethasone—psoriasis	4.21e-05	0.000271	CcSEcCtD
Carvedilol—Pruritus—Cyclosporine—psoriasis	4.2e-05	0.00027	CcSEcCtD
Carvedilol—Urticaria—Hydrocortisone—psoriasis	4.19e-05	0.00027	CcSEcCtD
Carvedilol—Angiopathy—Methotrexate—psoriasis	4.19e-05	0.00027	CcSEcCtD
Carvedilol—Immune system disorder—Methotrexate—psoriasis	4.17e-05	0.000268	CcSEcCtD
Carvedilol—Abdominal pain—Hydrocortisone—psoriasis	4.17e-05	0.000268	CcSEcCtD
Carvedilol—Body temperature increased—Hydrocortisone—psoriasis	4.17e-05	0.000268	CcSEcCtD
Carvedilol—Convulsion—Prednisone—psoriasis	4.17e-05	0.000268	CcSEcCtD
Carvedilol—Mediastinal disorder—Methotrexate—psoriasis	4.16e-05	0.000268	CcSEcCtD
Carvedilol—Asthenia—Mycophenolate mofetil—psoriasis	4.16e-05	0.000267	CcSEcCtD
Carvedilol—Hypertension—Prednisone—psoriasis	4.15e-05	0.000267	CcSEcCtD
Carvedilol—Musculoskeletal discomfort—Betamethasone—psoriasis	4.11e-05	0.000264	CcSEcCtD
Carvedilol—Musculoskeletal discomfort—Dexamethasone—psoriasis	4.11e-05	0.000264	CcSEcCtD
Carvedilol—Pruritus—Mycophenolate mofetil—psoriasis	4.1e-05	0.000264	CcSEcCtD
Carvedilol—Arthralgia—Prednisone—psoriasis	4.1e-05	0.000264	CcSEcCtD
Carvedilol—Myalgia—Prednisone—psoriasis	4.1e-05	0.000264	CcSEcCtD
Carvedilol—Feeling abnormal—Triamcinolone—psoriasis	4.1e-05	0.000263	CcSEcCtD
Carvedilol—Alopecia—Methotrexate—psoriasis	4.08e-05	0.000263	CcSEcCtD
Carvedilol—Insomnia—Dexamethasone—psoriasis	4.08e-05	0.000262	CcSEcCtD
Carvedilol—Insomnia—Betamethasone—psoriasis	4.08e-05	0.000262	CcSEcCtD
Carvedilol—Unspecified disorder of skin and subcutaneous tissue—Prednisone—psoriasis	4.07e-05	0.000262	CcSEcCtD
Carvedilol—Diarrhoea—Cyclosporine—psoriasis	4.06e-05	0.000261	CcSEcCtD
Carvedilol—Paraesthesia—Betamethasone—psoriasis	4.05e-05	0.000261	CcSEcCtD
Carvedilol—Paraesthesia—Dexamethasone—psoriasis	4.05e-05	0.000261	CcSEcCtD
Carvedilol—Discomfort—Prednisone—psoriasis	4.05e-05	0.00026	CcSEcCtD
Carvedilol—Malnutrition—Methotrexate—psoriasis	4.02e-05	0.000259	CcSEcCtD
Carvedilol—Hypersensitivity—Prednisolone—psoriasis	3.98e-05	0.000256	CcSEcCtD
Carvedilol—Dyspepsia—Dexamethasone—psoriasis	3.97e-05	0.000255	CcSEcCtD
Carvedilol—Dyspepsia—Betamethasone—psoriasis	3.97e-05	0.000255	CcSEcCtD
Carvedilol—Diarrhoea—Mycophenolate mofetil—psoriasis	3.96e-05	0.000255	CcSEcCtD
Carvedilol—Urticaria—Triamcinolone—psoriasis	3.95e-05	0.000254	CcSEcCtD
Carvedilol—Body temperature increased—Triamcinolone—psoriasis	3.93e-05	0.000253	CcSEcCtD
Carvedilol—Dizziness—Cyclosporine—psoriasis	3.93e-05	0.000253	CcSEcCtD
Carvedilol—Oedema—Prednisone—psoriasis	3.93e-05	0.000253	CcSEcCtD
Carvedilol—Anaphylactic shock—Prednisone—psoriasis	3.93e-05	0.000253	CcSEcCtD
Carvedilol—Decreased appetite—Betamethasone—psoriasis	3.92e-05	0.000252	CcSEcCtD
Carvedilol—Decreased appetite—Dexamethasone—psoriasis	3.92e-05	0.000252	CcSEcCtD
Carvedilol—Infection—Prednisone—psoriasis	3.9e-05	0.000251	CcSEcCtD
Carvedilol—Gastrointestinal disorder—Betamethasone—psoriasis	3.89e-05	0.00025	CcSEcCtD
Carvedilol—Gastrointestinal disorder—Dexamethasone—psoriasis	3.89e-05	0.00025	CcSEcCtD
Carvedilol—Back pain—Methotrexate—psoriasis	3.89e-05	0.00025	CcSEcCtD
Carvedilol—Hypersensitivity—Hydrocortisone—psoriasis	3.89e-05	0.00025	CcSEcCtD
Carvedilol—Fatigue—Betamethasone—psoriasis	3.89e-05	0.00025	CcSEcCtD
Carvedilol—Fatigue—Dexamethasone—psoriasis	3.89e-05	0.00025	CcSEcCtD
Carvedilol—Shock—Prednisone—psoriasis	3.86e-05	0.000249	CcSEcCtD
Carvedilol—Pain—Betamethasone—psoriasis	3.86e-05	0.000248	CcSEcCtD
Carvedilol—Pain—Dexamethasone—psoriasis	3.86e-05	0.000248	CcSEcCtD
Carvedilol—Tachycardia—Prednisone—psoriasis	3.83e-05	0.000247	CcSEcCtD
Carvedilol—Dizziness—Mycophenolate mofetil—psoriasis	3.83e-05	0.000246	CcSEcCtD
Carvedilol—Skin disorder—Prednisone—psoriasis	3.81e-05	0.000245	CcSEcCtD
Carvedilol—Hyperhidrosis—Prednisone—psoriasis	3.8e-05	0.000244	CcSEcCtD
Carvedilol—Vision blurred—Methotrexate—psoriasis	3.79e-05	0.000244	CcSEcCtD
Carvedilol—Asthenia—Hydrocortisone—psoriasis	3.79e-05	0.000244	CcSEcCtD
Carvedilol—Vomiting—Cyclosporine—psoriasis	3.78e-05	0.000243	CcSEcCtD
Carvedilol—Rash—Cyclosporine—psoriasis	3.74e-05	0.000241	CcSEcCtD
Carvedilol—Anorexia—Prednisone—psoriasis	3.74e-05	0.000241	CcSEcCtD
Carvedilol—Dermatitis—Cyclosporine—psoriasis	3.74e-05	0.000241	CcSEcCtD
Carvedilol—Pruritus—Hydrocortisone—psoriasis	3.73e-05	0.00024	CcSEcCtD
Carvedilol—Ill-defined disorder—Methotrexate—psoriasis	3.73e-05	0.00024	CcSEcCtD
Carvedilol—Headache—Cyclosporine—psoriasis	3.72e-05	0.000239	CcSEcCtD
Carvedilol—Anaemia—Methotrexate—psoriasis	3.72e-05	0.000239	CcSEcCtD
Carvedilol—Feeling abnormal—Betamethasone—psoriasis	3.72e-05	0.000239	CcSEcCtD
Carvedilol—Feeling abnormal—Dexamethasone—psoriasis	3.72e-05	0.000239	CcSEcCtD
Carvedilol—Gastrointestinal pain—Dexamethasone—psoriasis	3.69e-05	0.000237	CcSEcCtD
Carvedilol—Gastrointestinal pain—Betamethasone—psoriasis	3.69e-05	0.000237	CcSEcCtD
Carvedilol—Vomiting—Mycophenolate mofetil—psoriasis	3.68e-05	0.000237	CcSEcCtD
Carvedilol—Hypersensitivity—Triamcinolone—psoriasis	3.66e-05	0.000236	CcSEcCtD
Carvedilol—Rash—Mycophenolate mofetil—psoriasis	3.65e-05	0.000235	CcSEcCtD
Carvedilol—Dermatitis—Mycophenolate mofetil—psoriasis	3.65e-05	0.000235	CcSEcCtD
Carvedilol—Headache—Mycophenolate mofetil—psoriasis	3.63e-05	0.000234	CcSEcCtD
Carvedilol—Malaise—Methotrexate—psoriasis	3.63e-05	0.000233	CcSEcCtD
Carvedilol—Vertigo—Methotrexate—psoriasis	3.61e-05	0.000232	CcSEcCtD
Carvedilol—Diarrhoea—Hydrocortisone—psoriasis	3.61e-05	0.000232	CcSEcCtD
Carvedilol—Leukopenia—Methotrexate—psoriasis	3.6e-05	0.000232	CcSEcCtD
Carvedilol—Urticaria—Betamethasone—psoriasis	3.58e-05	0.00023	CcSEcCtD
Carvedilol—Urticaria—Dexamethasone—psoriasis	3.58e-05	0.00023	CcSEcCtD
Carvedilol—Musculoskeletal discomfort—Prednisone—psoriasis	3.58e-05	0.00023	CcSEcCtD
Carvedilol—Dizziness—Prednisolone—psoriasis	3.57e-05	0.00023	CcSEcCtD
Carvedilol—Asthenia—Triamcinolone—psoriasis	3.57e-05	0.000229	CcSEcCtD
Carvedilol—Abdominal pain—Betamethasone—psoriasis	3.56e-05	0.000229	CcSEcCtD
Carvedilol—Abdominal pain—Dexamethasone—psoriasis	3.56e-05	0.000229	CcSEcCtD
Carvedilol—Body temperature increased—Betamethasone—psoriasis	3.56e-05	0.000229	CcSEcCtD
Carvedilol—Body temperature increased—Dexamethasone—psoriasis	3.56e-05	0.000229	CcSEcCtD
Carvedilol—Insomnia—Prednisone—psoriasis	3.55e-05	0.000229	CcSEcCtD
Carvedilol—Nausea—Cyclosporine—psoriasis	3.53e-05	0.000227	CcSEcCtD
Carvedilol—Paraesthesia—Prednisone—psoriasis	3.53e-05	0.000227	CcSEcCtD
Carvedilol—Pruritus—Triamcinolone—psoriasis	3.52e-05	0.000226	CcSEcCtD
Carvedilol—Cough—Methotrexate—psoriasis	3.51e-05	0.000226	CcSEcCtD
Carvedilol—Dizziness—Hydrocortisone—psoriasis	3.49e-05	0.000225	CcSEcCtD
Carvedilol—Convulsion—Methotrexate—psoriasis	3.48e-05	0.000224	CcSEcCtD
Carvedilol—Dyspepsia—Prednisone—psoriasis	3.46e-05	0.000222	CcSEcCtD
Carvedilol—Nausea—Mycophenolate mofetil—psoriasis	3.44e-05	0.000221	CcSEcCtD
Carvedilol—Chest pain—Methotrexate—psoriasis	3.42e-05	0.00022	CcSEcCtD
Carvedilol—Myalgia—Methotrexate—psoriasis	3.42e-05	0.00022	CcSEcCtD
Carvedilol—Arthralgia—Methotrexate—psoriasis	3.42e-05	0.00022	CcSEcCtD
Carvedilol—Decreased appetite—Prednisone—psoriasis	3.41e-05	0.00022	CcSEcCtD
Carvedilol—Rash—Prednisolone—psoriasis	3.41e-05	0.000219	CcSEcCtD
Carvedilol—Dermatitis—Prednisolone—psoriasis	3.4e-05	0.000219	CcSEcCtD
Carvedilol—Unspecified disorder of skin and subcutaneous tissue—Methotrexate—psoriasis	3.4e-05	0.000219	CcSEcCtD
Carvedilol—Fatigue—Prednisone—psoriasis	3.39e-05	0.000218	CcSEcCtD
Carvedilol—Headache—Prednisolone—psoriasis	3.39e-05	0.000218	CcSEcCtD
Carvedilol—Discomfort—Methotrexate—psoriasis	3.38e-05	0.000218	CcSEcCtD
Carvedilol—Constipation—Prednisone—psoriasis	3.36e-05	0.000216	CcSEcCtD
Carvedilol—Vomiting—Hydrocortisone—psoriasis	3.36e-05	0.000216	CcSEcCtD
Carvedilol—Rash—Hydrocortisone—psoriasis	3.33e-05	0.000214	CcSEcCtD
Carvedilol—Dermatitis—Hydrocortisone—psoriasis	3.33e-05	0.000214	CcSEcCtD
Carvedilol—Confusional state—Methotrexate—psoriasis	3.31e-05	0.000213	CcSEcCtD
Carvedilol—Headache—Hydrocortisone—psoriasis	3.31e-05	0.000213	CcSEcCtD
Carvedilol—Dizziness—Triamcinolone—psoriasis	3.29e-05	0.000211	CcSEcCtD
Carvedilol—Anaphylactic shock—Methotrexate—psoriasis	3.28e-05	0.000211	CcSEcCtD
Carvedilol—Infection—Methotrexate—psoriasis	3.26e-05	0.00021	CcSEcCtD
Carvedilol—Feeling abnormal—Prednisone—psoriasis	3.24e-05	0.000208	CcSEcCtD
Carvedilol—Asthenia—Betamethasone—psoriasis	3.24e-05	0.000208	CcSEcCtD
Carvedilol—Asthenia—Dexamethasone—psoriasis	3.24e-05	0.000208	CcSEcCtD
Carvedilol—Thrombocytopenia—Methotrexate—psoriasis	3.21e-05	0.000207	CcSEcCtD
Carvedilol—Gastrointestinal pain—Prednisone—psoriasis	3.21e-05	0.000207	CcSEcCtD
Carvedilol—Nausea—Prednisolone—psoriasis	3.21e-05	0.000207	CcSEcCtD
Carvedilol—Pruritus—Dexamethasone—psoriasis	3.19e-05	0.000205	CcSEcCtD
Carvedilol—Pruritus—Betamethasone—psoriasis	3.19e-05	0.000205	CcSEcCtD
Carvedilol—Skin disorder—Methotrexate—psoriasis	3.19e-05	0.000205	CcSEcCtD
Carvedilol—Hyperhidrosis—Methotrexate—psoriasis	3.17e-05	0.000204	CcSEcCtD
Carvedilol—Vomiting—Triamcinolone—psoriasis	3.16e-05	0.000203	CcSEcCtD
Carvedilol—Nausea—Hydrocortisone—psoriasis	3.14e-05	0.000202	CcSEcCtD
Carvedilol—Rash—Triamcinolone—psoriasis	3.13e-05	0.000202	CcSEcCtD
Carvedilol—Dermatitis—Triamcinolone—psoriasis	3.13e-05	0.000201	CcSEcCtD
Carvedilol—Anorexia—Methotrexate—psoriasis	3.13e-05	0.000201	CcSEcCtD
Carvedilol—Urticaria—Prednisone—psoriasis	3.12e-05	0.000201	CcSEcCtD
Carvedilol—Headache—Triamcinolone—psoriasis	3.11e-05	0.0002	CcSEcCtD
Carvedilol—Abdominal pain—Prednisone—psoriasis	3.1e-05	0.0002	CcSEcCtD
Carvedilol—Body temperature increased—Prednisone—psoriasis	3.1e-05	0.0002	CcSEcCtD
Carvedilol—Diarrhoea—Betamethasone—psoriasis	3.09e-05	0.000199	CcSEcCtD
Carvedilol—Diarrhoea—Dexamethasone—psoriasis	3.09e-05	0.000199	CcSEcCtD
Carvedilol—Hypotension—Methotrexate—psoriasis	3.07e-05	0.000197	CcSEcCtD
Carvedilol—Musculoskeletal discomfort—Methotrexate—psoriasis	2.99e-05	0.000192	CcSEcCtD
Carvedilol—Dizziness—Betamethasone—psoriasis	2.98e-05	0.000192	CcSEcCtD
Carvedilol—Dizziness—Dexamethasone—psoriasis	2.98e-05	0.000192	CcSEcCtD
Carvedilol—Insomnia—Methotrexate—psoriasis	2.97e-05	0.000191	CcSEcCtD
Carvedilol—GJA1—Betamethasone—Hydrocortisone—psoriasis	2.97e-05	0.0074	CbGdCrCtD
Carvedilol—GJA1—Dexamethasone—Hydrocortisone—psoriasis	2.97e-05	0.0074	CbGdCrCtD
Carvedilol—Nausea—Triamcinolone—psoriasis	2.95e-05	0.00019	CcSEcCtD
Carvedilol—Paraesthesia—Methotrexate—psoriasis	2.95e-05	0.00019	CcSEcCtD
Carvedilol—Dyspnoea—Methotrexate—psoriasis	2.93e-05	0.000188	CcSEcCtD
Carvedilol—Somnolence—Methotrexate—psoriasis	2.92e-05	0.000188	CcSEcCtD
Carvedilol—Hypersensitivity—Prednisone—psoriasis	2.89e-05	0.000186	CcSEcCtD
Carvedilol—Dyspepsia—Methotrexate—psoriasis	2.89e-05	0.000186	CcSEcCtD
Carvedilol—Vomiting—Dexamethasone—psoriasis	2.87e-05	0.000184	CcSEcCtD
Carvedilol—Vomiting—Betamethasone—psoriasis	2.87e-05	0.000184	CcSEcCtD
Carvedilol—Decreased appetite—Methotrexate—psoriasis	2.85e-05	0.000184	CcSEcCtD
Carvedilol—Rash—Betamethasone—psoriasis	2.84e-05	0.000183	CcSEcCtD
Carvedilol—Rash—Dexamethasone—psoriasis	2.84e-05	0.000183	CcSEcCtD
Carvedilol—Dermatitis—Betamethasone—psoriasis	2.84e-05	0.000183	CcSEcCtD
Carvedilol—Dermatitis—Dexamethasone—psoriasis	2.84e-05	0.000183	CcSEcCtD
Carvedilol—Gastrointestinal disorder—Methotrexate—psoriasis	2.83e-05	0.000182	CcSEcCtD
Carvedilol—Fatigue—Methotrexate—psoriasis	2.83e-05	0.000182	CcSEcCtD
Carvedilol—Headache—Betamethasone—psoriasis	2.83e-05	0.000182	CcSEcCtD
Carvedilol—Headache—Dexamethasone—psoriasis	2.83e-05	0.000182	CcSEcCtD
Carvedilol—Asthenia—Prednisone—psoriasis	2.82e-05	0.000181	CcSEcCtD
Carvedilol—Pain—Methotrexate—psoriasis	2.81e-05	0.000181	CcSEcCtD
Carvedilol—Pruritus—Prednisone—psoriasis	2.78e-05	0.000179	CcSEcCtD
Carvedilol—GJA1—Dexamethasone—Betamethasone—psoriasis	2.75e-05	0.00687	CbGdCrCtD
Carvedilol—GJA1—Betamethasone—Dexamethasone—psoriasis	2.75e-05	0.00687	CbGdCrCtD
Carvedilol—Feeling abnormal—Methotrexate—psoriasis	2.7e-05	0.000174	CcSEcCtD
Carvedilol—GJA1—Dexamethasone—Triamcinolone—psoriasis	2.69e-05	0.00671	CbGdCrCtD
Carvedilol—GJA1—Betamethasone—Triamcinolone—psoriasis	2.69e-05	0.00671	CbGdCrCtD
Carvedilol—Diarrhoea—Prednisone—psoriasis	2.69e-05	0.000173	CcSEcCtD
Carvedilol—Gastrointestinal pain—Methotrexate—psoriasis	2.68e-05	0.000173	CcSEcCtD
Carvedilol—Nausea—Betamethasone—psoriasis	2.68e-05	0.000172	CcSEcCtD
Carvedilol—Nausea—Dexamethasone—psoriasis	2.68e-05	0.000172	CcSEcCtD
Carvedilol—VEGFA—Dexamethasone—Hydrocortisone—psoriasis	2.61e-05	0.00652	CbGdCrCtD
Carvedilol—VEGFA—Betamethasone—Hydrocortisone—psoriasis	2.61e-05	0.00652	CbGdCrCtD
Carvedilol—Urticaria—Methotrexate—psoriasis	2.61e-05	0.000168	CcSEcCtD
Carvedilol—Dizziness—Prednisone—psoriasis	2.6e-05	0.000167	CcSEcCtD
Carvedilol—Abdominal pain—Methotrexate—psoriasis	2.59e-05	0.000167	CcSEcCtD
Carvedilol—Body temperature increased—Methotrexate—psoriasis	2.59e-05	0.000167	CcSEcCtD
Carvedilol—GJA1—Dexamethasone—Prednisone—psoriasis	2.55e-05	0.00637	CbGdCrCtD
Carvedilol—GJA1—Betamethasone—Prednisone—psoriasis	2.55e-05	0.00637	CbGdCrCtD
Carvedilol—Vomiting—Prednisone—psoriasis	2.5e-05	0.000161	CcSEcCtD
Carvedilol—GJA1—Dexamethasone—Prednisolone—psoriasis	2.49e-05	0.00622	CbGdCrCtD
Carvedilol—GJA1—Betamethasone—Prednisolone—psoriasis	2.49e-05	0.00622	CbGdCrCtD
Carvedilol—Rash—Prednisone—psoriasis	2.48e-05	0.000159	CcSEcCtD
Carvedilol—Dermatitis—Prednisone—psoriasis	2.47e-05	0.000159	CcSEcCtD
Carvedilol—Headache—Prednisone—psoriasis	2.46e-05	0.000158	CcSEcCtD
Carvedilol—VEGFA—Dexamethasone—Betamethasone—psoriasis	2.43e-05	0.00605	CbGdCrCtD
Carvedilol—VEGFA—Betamethasone—Dexamethasone—psoriasis	2.43e-05	0.00605	CbGdCrCtD
Carvedilol—Hypersensitivity—Methotrexate—psoriasis	2.42e-05	0.000156	CcSEcCtD
Carvedilol—VEGFA—Betamethasone—Triamcinolone—psoriasis	2.37e-05	0.00591	CbGdCrCtD
Carvedilol—VEGFA—Dexamethasone—Triamcinolone—psoriasis	2.37e-05	0.00591	CbGdCrCtD
Carvedilol—Asthenia—Methotrexate—psoriasis	2.35e-05	0.000152	CcSEcCtD
Carvedilol—Nausea—Prednisone—psoriasis	2.33e-05	0.00015	CcSEcCtD
Carvedilol—Pruritus—Methotrexate—psoriasis	2.32e-05	0.000149	CcSEcCtD
Carvedilol—VEGFA—Dexamethasone—Prednisone—psoriasis	2.25e-05	0.00561	CbGdCrCtD
Carvedilol—VEGFA—Betamethasone—Prednisone—psoriasis	2.25e-05	0.00561	CbGdCrCtD
Carvedilol—Diarrhoea—Methotrexate—psoriasis	2.25e-05	0.000144	CcSEcCtD
Carvedilol—VEGFA—Dexamethasone—Prednisolone—psoriasis	2.2e-05	0.00548	CbGdCrCtD
Carvedilol—VEGFA—Betamethasone—Prednisolone—psoriasis	2.2e-05	0.00548	CbGdCrCtD
Carvedilol—Dizziness—Methotrexate—psoriasis	2.17e-05	0.00014	CcSEcCtD
Carvedilol—Vomiting—Methotrexate—psoriasis	2.09e-05	0.000134	CcSEcCtD
Carvedilol—Rash—Methotrexate—psoriasis	2.07e-05	0.000133	CcSEcCtD
Carvedilol—Dermatitis—Methotrexate—psoriasis	2.07e-05	0.000133	CcSEcCtD
Carvedilol—Headache—Methotrexate—psoriasis	2.06e-05	0.000132	CcSEcCtD
Carvedilol—Nausea—Methotrexate—psoriasis	1.95e-05	0.000125	CcSEcCtD
Carvedilol—ADRA2B—Signaling Pathways—CCL20—psoriasis	1.03e-05	8.56e-05	CbGpPWpGaD
Carvedilol—ADRB2—Signaling Pathways—CCL20—psoriasis	1.02e-05	8.45e-05	CbGpPWpGaD
Carvedilol—HIF1A—Signaling Pathways—JUN—psoriasis	1.02e-05	8.45e-05	CbGpPWpGaD
Carvedilol—ADRA1D—GPCR ligand binding—CXCL8—psoriasis	1.02e-05	8.45e-05	CbGpPWpGaD
Carvedilol—ADRA1D—Gastrin-CREB signalling pathway via PKC and MAPK—IL6—psoriasis	1.02e-05	8.42e-05	CbGpPWpGaD
Carvedilol—XDH—Metabolism—APOE—psoriasis	1e-05	8.29e-05	CbGpPWpGaD
Carvedilol—VEGFA—Developmental Biology—TNF—psoriasis	9.91e-06	8.21e-05	CbGpPWpGaD
Carvedilol—CYP1A2—Metabolism of lipids and lipoproteins—CARM1—psoriasis	9.88e-06	8.19e-05	CbGpPWpGaD
Carvedilol—ADRA1A—Class A/1 (Rhodopsin-like receptors)—CXCL8—psoriasis	9.87e-06	8.18e-05	CbGpPWpGaD
Carvedilol—ADRA2A—Platelet activation, signaling and aggregation—VEGFA—psoriasis	9.84e-06	8.15e-05	CbGpPWpGaD
Carvedilol—HIF1A—Signaling Pathways—NFKB1—psoriasis	9.82e-06	8.14e-05	CbGpPWpGaD
Carvedilol—ADRA2C—Metabolism—CARM1—psoriasis	9.81e-06	8.13e-05	CbGpPWpGaD
Carvedilol—PTGS1—Metabolism—CARM1—psoriasis	9.8e-06	8.12e-05	CbGpPWpGaD
Carvedilol—ADRB3—Signaling Pathways—SOCS1—psoriasis	9.67e-06	8.02e-05	CbGpPWpGaD
Carvedilol—VEGFA—Signaling Pathways—SOCS1—psoriasis	9.65e-06	8e-05	CbGpPWpGaD
Carvedilol—ADRA2C—Signaling Pathways—CCL20—psoriasis	9.65e-06	8e-05	CbGpPWpGaD
Carvedilol—ADRA1B—Signaling Pathways—CCL20—psoriasis	9.5e-06	7.87e-05	CbGpPWpGaD
Carvedilol—ADRB1—GPCR ligand binding—CXCL8—psoriasis	9.29e-06	7.7e-05	CbGpPWpGaD
Carvedilol—ADRB3—Signaling by GPCR—TYK2—psoriasis	9.22e-06	7.64e-05	CbGpPWpGaD
Carvedilol—ADRA2B—GPCR ligand binding—CXCL8—psoriasis	9.2e-06	7.63e-05	CbGpPWpGaD
Carvedilol—ADRA2A—Class A/1 (Rhodopsin-like receptors)—CXCL8—psoriasis	9.17e-06	7.6e-05	CbGpPWpGaD
Carvedilol—PTGS1—Metabolism of lipids and lipoproteins—PPARG—psoriasis	9.16e-06	7.59e-05	CbGpPWpGaD
Carvedilol—ADRB2—GPCR ligand binding—CXCL8—psoriasis	9.09e-06	7.53e-05	CbGpPWpGaD
Carvedilol—CYP1A2—Metabolism—CYP2S1—psoriasis	9.01e-06	7.47e-05	CbGpPWpGaD
Carvedilol—HIF1A—Signaling Pathways—VEGFA—psoriasis	8.91e-06	7.38e-05	CbGpPWpGaD
Carvedilol—ADRB3—GPCR downstream signaling—CXCL8—psoriasis	8.84e-06	7.33e-05	CbGpPWpGaD
Carvedilol—HIF1A—Signaling Pathways—STAT3—psoriasis	8.82e-06	7.31e-05	CbGpPWpGaD
Carvedilol—HIF1A—Disease—IL6—psoriasis	8.8e-06	7.29e-05	CbGpPWpGaD
Carvedilol—ADRA2A—Hemostasis—NOS2—psoriasis	8.76e-06	7.26e-05	CbGpPWpGaD
Carvedilol—ABCB1—Integrated Pancreatic Cancer Pathway—JUN—psoriasis	8.75e-06	7.25e-05	CbGpPWpGaD
Carvedilol—XDH—Metabolism—PPARG—psoriasis	8.71e-06	7.22e-05	CbGpPWpGaD
Carvedilol—ADRA2C—GPCR ligand binding—CXCL8—psoriasis	8.6e-06	7.12e-05	CbGpPWpGaD
Carvedilol—VEGFA—Hemostasis—TP53—psoriasis	8.57e-06	7.1e-05	CbGpPWpGaD
Carvedilol—ADRA1B—GPCR ligand binding—CXCL8—psoriasis	8.46e-06	7.01e-05	CbGpPWpGaD
Carvedilol—ADRA1A—Signaling Pathways—CCL20—psoriasis	8.44e-06	6.99e-05	CbGpPWpGaD
Carvedilol—ADRA1B—Gastrin-CREB signalling pathway via PKC and MAPK—IL6—psoriasis	8.43e-06	6.99e-05	CbGpPWpGaD
Carvedilol—ABCB1—Integrated Pancreatic Cancer Pathway—NFKB1—psoriasis	8.42e-06	6.98e-05	CbGpPWpGaD
Carvedilol—CYP3A4—Metabolism—NDUFA5—psoriasis	8.18e-06	6.78e-05	CbGpPWpGaD
Carvedilol—ADRB3—Signaling by GPCR—CXCL8—psoriasis	8.03e-06	6.66e-05	CbGpPWpGaD
Carvedilol—VEGFA—Developmental Biology—IL6—psoriasis	8e-06	6.63e-05	CbGpPWpGaD
Carvedilol—ADRA2A—Metabolism—CARM1—psoriasis	7.97e-06	6.61e-05	CbGpPWpGaD
Carvedilol—ADRA2A—Signaling Pathways—CCL20—psoriasis	7.84e-06	6.5e-05	CbGpPWpGaD
Carvedilol—ABCB1—Integrated Pancreatic Cancer Pathway—VEGFA—psoriasis	7.65e-06	6.34e-05	CbGpPWpGaD
Carvedilol—ADRA1A—GPCR ligand binding—CXCL8—psoriasis	7.52e-06	6.23e-05	CbGpPWpGaD
Carvedilol—ADRA1A—Gastrin-CREB signalling pathway via PKC and MAPK—IL6—psoriasis	7.49e-06	6.2e-05	CbGpPWpGaD
Carvedilol—CYP1A1—Metabolism of lipids and lipoproteins—APOE—psoriasis	7.41e-06	6.14e-05	CbGpPWpGaD
Carvedilol—CYP2E1—Metabolism—CARM1—psoriasis	7.32e-06	6.07e-05	CbGpPWpGaD
Carvedilol—ADRB3—Signaling Pathways—APOE—psoriasis	7.14e-06	5.92e-05	CbGpPWpGaD
Carvedilol—ADRB3—Signaling Pathways—LEP—psoriasis	7.14e-06	5.92e-05	CbGpPWpGaD
Carvedilol—VEGFA—Signaling Pathways—APOE—psoriasis	7.12e-06	5.9e-05	CbGpPWpGaD
Carvedilol—VEGFA—Signaling Pathways—LEP—psoriasis	7.12e-06	5.9e-05	CbGpPWpGaD
Carvedilol—ADRA2A—GPCR ligand binding—CXCL8—psoriasis	6.98e-06	5.79e-05	CbGpPWpGaD
Carvedilol—CYP3A4—Metabolism—CYP2S1—psoriasis	6.95e-06	5.76e-05	CbGpPWpGaD
Carvedilol—CYP1A1—Metabolism—CARM1—psoriasis	6.9e-06	5.72e-05	CbGpPWpGaD
Carvedilol—HIF1A—Signaling Pathways—TP53—psoriasis	6.73e-06	5.58e-05	CbGpPWpGaD
Carvedilol—ADRA2B—Hemostasis—VEGFA—psoriasis	6.68e-06	5.54e-05	CbGpPWpGaD
Carvedilol—ADRB3—Signaling Pathways—NFKBIA—psoriasis	6.65e-06	5.51e-05	CbGpPWpGaD
Carvedilol—VEGFA—Signaling Pathways—NFKBIA—psoriasis	6.64e-06	5.5e-05	CbGpPWpGaD
Carvedilol—ABCB1—Integrated Pancreatic Cancer Pathway—TNF—psoriasis	6.55e-06	5.43e-05	CbGpPWpGaD
Carvedilol—CYP1A1—Metabolism of lipids and lipoproteins—PPARG—psoriasis	6.45e-06	5.35e-05	CbGpPWpGaD
Carvedilol—ADRA1D—Signaling Pathways—SOCS1—psoriasis	6.3e-06	5.22e-05	CbGpPWpGaD
Carvedilol—ADRA2C—Hemostasis—VEGFA—psoriasis	6.24e-06	5.17e-05	CbGpPWpGaD
Carvedilol—HIF1A—Signaling Pathways—IL6—psoriasis	6.16e-06	5.11e-05	CbGpPWpGaD
Carvedilol—ADRA2C—Metabolism—CAT—psoriasis	6.04e-06	5e-05	CbGpPWpGaD
Carvedilol—PTGS1—Metabolism—CAT—psoriasis	6.03e-06	4.99e-05	CbGpPWpGaD
Carvedilol—ADRA1D—Signaling by GPCR—TYK2—psoriasis	6.01e-06	4.98e-05	CbGpPWpGaD
Carvedilol—ABCB1—Integrated Pancreatic Cancer Pathway—TP53—psoriasis	5.78e-06	4.79e-05	CbGpPWpGaD
Carvedilol—ADRA1D—GPCR downstream signaling—CXCL8—psoriasis	5.76e-06	4.77e-05	CbGpPWpGaD
Carvedilol—ADRB1—Signaling Pathways—SOCS1—psoriasis	5.74e-06	4.76e-05	CbGpPWpGaD
Carvedilol—ADRA2B—Signaling Pathways—SOCS1—psoriasis	5.69e-06	4.72e-05	CbGpPWpGaD
Carvedilol—ADRB2—Signaling Pathways—SOCS1—psoriasis	5.62e-06	4.66e-05	CbGpPWpGaD
Carvedilol—CYP2C9—Metabolism of lipids and lipoproteins—APOE—psoriasis	5.53e-06	4.58e-05	CbGpPWpGaD
Carvedilol—ABCB1—Metabolism—CARM1—psoriasis	5.51e-06	4.57e-05	CbGpPWpGaD
Carvedilol—ADRB1—Signaling by GPCR—TYK2—psoriasis	5.47e-06	4.54e-05	CbGpPWpGaD
Carvedilol—ADRB3—Signaling Pathways—TYK2—psoriasis	5.45e-06	4.52e-05	CbGpPWpGaD
Carvedilol—VEGFA—Signaling Pathways—TYK2—psoriasis	5.44e-06	4.51e-05	CbGpPWpGaD
Carvedilol—ADRA2B—Signaling by GPCR—TYK2—psoriasis	5.42e-06	4.5e-05	CbGpPWpGaD
Carvedilol—ADRB2—Signaling by GPCR—TYK2—psoriasis	5.36e-06	4.44e-05	CbGpPWpGaD
Carvedilol—ADRA2C—Signaling Pathways—SOCS1—psoriasis	5.31e-06	4.4e-05	CbGpPWpGaD
Carvedilol—ADRB1—GPCR downstream signaling—CXCL8—psoriasis	5.25e-06	4.35e-05	CbGpPWpGaD
Carvedilol—ADRA1D—Signaling by GPCR—CXCL8—psoriasis	5.23e-06	4.34e-05	CbGpPWpGaD
Carvedilol—ADRA1B—Signaling Pathways—SOCS1—psoriasis	5.23e-06	4.33e-05	CbGpPWpGaD
Carvedilol—ADRA2B—GPCR downstream signaling—CXCL8—psoriasis	5.2e-06	4.31e-05	CbGpPWpGaD
Carvedilol—CYP2D6—Metabolism—CARM1—psoriasis	5.19e-06	4.31e-05	CbGpPWpGaD
Carvedilol—CYP2C9—Metabolism—CARM1—psoriasis	5.15e-06	4.27e-05	CbGpPWpGaD
Carvedilol—ADRB2—GPCR downstream signaling—CXCL8—psoriasis	5.13e-06	4.26e-05	CbGpPWpGaD
Carvedilol—ADRA2A—Hemostasis—VEGFA—psoriasis	5.07e-06	4.2e-05	CbGpPWpGaD
Carvedilol—ADRA2C—Signaling by GPCR—TYK2—psoriasis	5.07e-06	4.2e-05	CbGpPWpGaD
Carvedilol—ADRA2B—Hemostasis—TP53—psoriasis	5.05e-06	4.19e-05	CbGpPWpGaD
Carvedilol—ADRA1B—Signaling by GPCR—TYK2—psoriasis	4.99e-06	4.13e-05	CbGpPWpGaD
Carvedilol—ADRA2A—Metabolism—CAT—psoriasis	4.9e-06	4.06e-05	CbGpPWpGaD
Carvedilol—ADRA2C—GPCR downstream signaling—CXCL8—psoriasis	4.86e-06	4.03e-05	CbGpPWpGaD
Carvedilol—CYP2C9—Metabolism of lipids and lipoproteins—PPARG—psoriasis	4.81e-06	3.99e-05	CbGpPWpGaD
Carvedilol—ADRA1B—GPCR downstream signaling—CXCL8—psoriasis	4.78e-06	3.96e-05	CbGpPWpGaD
Carvedilol—ADRB1—Signaling by GPCR—CXCL8—psoriasis	4.77e-06	3.95e-05	CbGpPWpGaD
Carvedilol—ADRB3—Signaling Pathways—CXCL8—psoriasis	4.74e-06	3.93e-05	CbGpPWpGaD
Carvedilol—VEGFA—Signaling Pathways—CXCL8—psoriasis	4.73e-06	3.92e-05	CbGpPWpGaD
Carvedilol—ADRA2B—Signaling by GPCR—CXCL8—psoriasis	4.72e-06	3.91e-05	CbGpPWpGaD
Carvedilol—CYP1A2—Metabolism of lipids and lipoproteins—APOE—psoriasis	4.72e-06	3.91e-05	CbGpPWpGaD
Carvedilol—ADRA2C—Hemostasis—TP53—psoriasis	4.72e-06	3.91e-05	CbGpPWpGaD
Carvedilol—ADRA2C—Metabolism—APOE—psoriasis	4.69e-06	3.89e-05	CbGpPWpGaD
Carvedilol—PTGS1—Metabolism—APOE—psoriasis	4.68e-06	3.88e-05	CbGpPWpGaD
Carvedilol—ADRB2—Signaling by GPCR—CXCL8—psoriasis	4.66e-06	3.86e-05	CbGpPWpGaD
Carvedilol—ADRA1D—Signaling Pathways—LEP—psoriasis	4.65e-06	3.85e-05	CbGpPWpGaD
Carvedilol—ADRA1D—Signaling Pathways—APOE—psoriasis	4.65e-06	3.85e-05	CbGpPWpGaD
Carvedilol—ADRA1A—Signaling Pathways—SOCS1—psoriasis	4.65e-06	3.85e-05	CbGpPWpGaD
Carvedilol—ADRB3—Signaling by GPCR—IL6—psoriasis	4.51e-06	3.74e-05	CbGpPWpGaD
Carvedilol—CYP2E1—Metabolism—CAT—psoriasis	4.5e-06	3.73e-05	CbGpPWpGaD
Carvedilol—ADRA1A—Signaling by GPCR—TYK2—psoriasis	4.43e-06	3.67e-05	CbGpPWpGaD
Carvedilol—ADRA2C—Signaling by GPCR—CXCL8—psoriasis	4.41e-06	3.66e-05	CbGpPWpGaD
Carvedilol—ADRB3—Signaling Pathways—JUN—psoriasis	4.41e-06	3.66e-05	CbGpPWpGaD
Carvedilol—VEGFA—Signaling Pathways—JUN—psoriasis	4.4e-06	3.65e-05	CbGpPWpGaD
Carvedilol—CYP1A2—Metabolism—CARM1—psoriasis	4.4e-06	3.65e-05	CbGpPWpGaD
Carvedilol—ADRA1B—Signaling by GPCR—CXCL8—psoriasis	4.34e-06	3.6e-05	CbGpPWpGaD
Carvedilol—ADRA1D—Signaling Pathways—NFKBIA—psoriasis	4.33e-06	3.59e-05	CbGpPWpGaD
Carvedilol—ADRA2A—Signaling Pathways—SOCS1—psoriasis	4.32e-06	3.58e-05	CbGpPWpGaD
Carvedilol—ADRA1A—GPCR downstream signaling—CXCL8—psoriasis	4.25e-06	3.52e-05	CbGpPWpGaD
Carvedilol—ADRB3—Signaling Pathways—NFKB1—psoriasis	4.25e-06	3.52e-05	CbGpPWpGaD
Carvedilol—CYP1A1—Metabolism—CAT—psoriasis	4.25e-06	3.52e-05	CbGpPWpGaD
Carvedilol—ADRB1—Signaling Pathways—APOE—psoriasis	4.24e-06	3.51e-05	CbGpPWpGaD
Carvedilol—ADRB1—Signaling Pathways—LEP—psoriasis	4.24e-06	3.51e-05	CbGpPWpGaD
Carvedilol—VEGFA—Signaling Pathways—NFKB1—psoriasis	4.24e-06	3.51e-05	CbGpPWpGaD
Carvedilol—ADRA2B—Signaling Pathways—LEP—psoriasis	4.2e-06	3.48e-05	CbGpPWpGaD
Carvedilol—ADRA2B—Signaling Pathways—APOE—psoriasis	4.2e-06	3.48e-05	CbGpPWpGaD
Carvedilol—ADRB2—Signaling Pathways—LEP—psoriasis	4.15e-06	3.44e-05	CbGpPWpGaD
Carvedilol—ADRB2—Signaling Pathways—APOE—psoriasis	4.15e-06	3.44e-05	CbGpPWpGaD
Carvedilol—ADRA2A—Signaling by GPCR—TYK2—psoriasis	4.12e-06	3.41e-05	CbGpPWpGaD
Carvedilol—CYP1A2—Metabolism of lipids and lipoproteins—PPARG—psoriasis	4.11e-06	3.41e-05	CbGpPWpGaD
Carvedilol—ADRA2C—Metabolism—PPARG—psoriasis	4.09e-06	3.39e-05	CbGpPWpGaD
Carvedilol—PTGS1—Metabolism—PPARG—psoriasis	4.08e-06	3.38e-05	CbGpPWpGaD
Carvedilol—ADRB1—Signaling Pathways—NFKBIA—psoriasis	3.95e-06	3.27e-05	CbGpPWpGaD
Carvedilol—ADRA2A—GPCR downstream signaling—CXCL8—psoriasis	3.95e-06	3.27e-05	CbGpPWpGaD
Carvedilol—ADRA2C—Signaling Pathways—APOE—psoriasis	3.92e-06	3.25e-05	CbGpPWpGaD
Carvedilol—ADRA2C—Signaling Pathways—LEP—psoriasis	3.92e-06	3.25e-05	CbGpPWpGaD
Carvedilol—ADRA2B—Signaling Pathways—NFKBIA—psoriasis	3.91e-06	3.24e-05	CbGpPWpGaD
Carvedilol—ADRB2—Signaling Pathways—NFKBIA—psoriasis	3.86e-06	3.2e-05	CbGpPWpGaD
Carvedilol—ADRA1B—Signaling Pathways—APOE—psoriasis	3.86e-06	3.2e-05	CbGpPWpGaD
Carvedilol—ADRA1B—Signaling Pathways—LEP—psoriasis	3.86e-06	3.2e-05	CbGpPWpGaD
Carvedilol—ADRA1A—Signaling by GPCR—CXCL8—psoriasis	3.86e-06	3.2e-05	CbGpPWpGaD
Carvedilol—ADRB3—Signaling Pathways—VEGFA—psoriasis	3.85e-06	3.19e-05	CbGpPWpGaD
Carvedilol—ADRA2A—Hemostasis—TP53—psoriasis	3.83e-06	3.18e-05	CbGpPWpGaD
Carvedilol—ADRB3—Signaling Pathways—STAT3—psoriasis	3.82e-06	3.16e-05	CbGpPWpGaD
Carvedilol—ADRA2A—Metabolism—APOE—psoriasis	3.81e-06	3.16e-05	CbGpPWpGaD
Carvedilol—VEGFA—Signaling Pathways—STAT3—psoriasis	3.81e-06	3.16e-05	CbGpPWpGaD
Carvedilol—ADRA2C—Signaling Pathways—NFKBIA—psoriasis	3.65e-06	3.03e-05	CbGpPWpGaD
Carvedilol—ADRA1B—Signaling Pathways—NFKBIA—psoriasis	3.6e-06	2.98e-05	CbGpPWpGaD
Carvedilol—ADRA2A—Signaling by GPCR—CXCL8—psoriasis	3.58e-06	2.97e-05	CbGpPWpGaD
Carvedilol—ADRA1D—Signaling Pathways—TYK2—psoriasis	3.55e-06	2.94e-05	CbGpPWpGaD
Carvedilol—CYP2E1—Metabolism—APOE—psoriasis	3.5e-06	2.9e-05	CbGpPWpGaD
Carvedilol—ADRA1A—Signaling Pathways—LEP—psoriasis	3.43e-06	2.84e-05	CbGpPWpGaD
Carvedilol—ADRA1A—Signaling Pathways—APOE—psoriasis	3.43e-06	2.84e-05	CbGpPWpGaD
Carvedilol—CYP3A4—Metabolism—CARM1—psoriasis	3.4e-06	2.81e-05	CbGpPWpGaD
Carvedilol—ABCB1—Metabolism—CAT—psoriasis	3.39e-06	2.81e-05	CbGpPWpGaD
Carvedilol—ADRA2A—Metabolism—PPARG—psoriasis	3.32e-06	2.75e-05	CbGpPWpGaD
Carvedilol—CYP1A1—Metabolism—APOE—psoriasis	3.3e-06	2.73e-05	CbGpPWpGaD
Carvedilol—ADRB1—Signaling Pathways—TYK2—psoriasis	3.23e-06	2.68e-05	CbGpPWpGaD
Carvedilol—ADRA2B—Signaling Pathways—TYK2—psoriasis	3.2e-06	2.66e-05	CbGpPWpGaD
Carvedilol—CYP2D6—Metabolism—CAT—psoriasis	3.2e-06	2.65e-05	CbGpPWpGaD
Carvedilol—ADRA1A—Signaling Pathways—NFKBIA—psoriasis	3.19e-06	2.65e-05	CbGpPWpGaD
Carvedilol—ADRA2A—Signaling Pathways—LEP—psoriasis	3.19e-06	2.64e-05	CbGpPWpGaD
Carvedilol—ADRA2A—Signaling Pathways—APOE—psoriasis	3.19e-06	2.64e-05	CbGpPWpGaD
Carvedilol—CYP2C9—Metabolism—CAT—psoriasis	3.17e-06	2.63e-05	CbGpPWpGaD
Carvedilol—ADRB2—Signaling Pathways—TYK2—psoriasis	3.16e-06	2.62e-05	CbGpPWpGaD
Carvedilol—ADRA1D—Signaling Pathways—CXCL8—psoriasis	3.09e-06	2.56e-05	CbGpPWpGaD
Carvedilol—CYP2E1—Metabolism—PPARG—psoriasis	3.05e-06	2.53e-05	CbGpPWpGaD
Carvedilol—ADRA2C—Signaling Pathways—TYK2—psoriasis	2.99e-06	2.48e-05	CbGpPWpGaD
Carvedilol—ADRA2A—Signaling Pathways—NFKBIA—psoriasis	2.97e-06	2.46e-05	CbGpPWpGaD
Carvedilol—ADRA1B—Signaling Pathways—TYK2—psoriasis	2.95e-06	2.44e-05	CbGpPWpGaD
Carvedilol—ADRA1D—Signaling by GPCR—IL6—psoriasis	2.94e-06	2.44e-05	CbGpPWpGaD
Carvedilol—ADRB3—Signaling Pathways—TP53—psoriasis	2.91e-06	2.41e-05	CbGpPWpGaD
Carvedilol—VEGFA—Signaling Pathways—TP53—psoriasis	2.91e-06	2.41e-05	CbGpPWpGaD
Carvedilol—ADRA1D—Signaling Pathways—JUN—psoriasis	2.87e-06	2.38e-05	CbGpPWpGaD
Carvedilol—CYP1A1—Metabolism—PPARG—psoriasis	2.87e-06	2.38e-05	CbGpPWpGaD
Carvedilol—ADRB1—Signaling Pathways—CXCL8—psoriasis	2.82e-06	2.33e-05	CbGpPWpGaD
Carvedilol—ADRA2B—Signaling Pathways—CXCL8—psoriasis	2.79e-06	2.31e-05	CbGpPWpGaD
Carvedilol—ADRA1D—Signaling Pathways—NFKB1—psoriasis	2.77e-06	2.29e-05	CbGpPWpGaD
Carvedilol—ADRB2—Signaling Pathways—CXCL8—psoriasis	2.75e-06	2.28e-05	CbGpPWpGaD
Carvedilol—CYP1A2—Metabolism—CAT—psoriasis	2.71e-06	2.24e-05	CbGpPWpGaD
Carvedilol—ADRB1—Signaling by GPCR—IL6—psoriasis	2.68e-06	2.22e-05	CbGpPWpGaD
Carvedilol—ADRB3—Signaling Pathways—IL6—psoriasis	2.67e-06	2.21e-05	CbGpPWpGaD
Carvedilol—VEGFA—Signaling Pathways—IL6—psoriasis	2.66e-06	2.2e-05	CbGpPWpGaD
Carvedilol—ADRA2B—Signaling by GPCR—IL6—psoriasis	2.65e-06	2.2e-05	CbGpPWpGaD
Carvedilol—ABCB1—Metabolism—APOE—psoriasis	2.63e-06	2.18e-05	CbGpPWpGaD
Carvedilol—ADRB2—Signaling by GPCR—IL6—psoriasis	2.62e-06	2.17e-05	CbGpPWpGaD
Carvedilol—ADRB1—Signaling Pathways—JUN—psoriasis	2.62e-06	2.17e-05	CbGpPWpGaD
Carvedilol—ADRA1A—Signaling Pathways—TYK2—psoriasis	2.62e-06	2.17e-05	CbGpPWpGaD
Carvedilol—ADRA2C—Signaling Pathways—CXCL8—psoriasis	2.61e-06	2.16e-05	CbGpPWpGaD
Carvedilol—ADRA2B—Signaling Pathways—JUN—psoriasis	2.59e-06	2.15e-05	CbGpPWpGaD
Carvedilol—ADRA1B—Signaling Pathways—CXCL8—psoriasis	2.57e-06	2.13e-05	CbGpPWpGaD
Carvedilol—ADRB2—Signaling Pathways—JUN—psoriasis	2.56e-06	2.12e-05	CbGpPWpGaD
Carvedilol—ADRB1—Signaling Pathways—NFKB1—psoriasis	2.52e-06	2.09e-05	CbGpPWpGaD
Carvedilol—ADRA1D—Signaling Pathways—VEGFA—psoriasis	2.51e-06	2.08e-05	CbGpPWpGaD
Carvedilol—ADRA2B—Signaling Pathways—NFKB1—psoriasis	2.5e-06	2.07e-05	CbGpPWpGaD
Carvedilol—ADRA1D—Signaling Pathways—STAT3—psoriasis	2.49e-06	2.06e-05	CbGpPWpGaD
Carvedilol—CYP2D6—Metabolism—APOE—psoriasis	2.48e-06	2.06e-05	CbGpPWpGaD
Carvedilol—ADRA2C—Signaling by GPCR—IL6—psoriasis	2.48e-06	2.05e-05	CbGpPWpGaD
Carvedilol—ADRB2—Signaling Pathways—NFKB1—psoriasis	2.47e-06	2.04e-05	CbGpPWpGaD
Carvedilol—CYP2C9—Metabolism—APOE—psoriasis	2.46e-06	2.04e-05	CbGpPWpGaD
Carvedilol—ADRA1B—Signaling by GPCR—IL6—psoriasis	2.44e-06	2.02e-05	CbGpPWpGaD
Carvedilol—ADRA2A—Signaling Pathways—TYK2—psoriasis	2.43e-06	2.02e-05	CbGpPWpGaD
Carvedilol—ADRA2C—Signaling Pathways—JUN—psoriasis	2.42e-06	2.01e-05	CbGpPWpGaD
Carvedilol—ADRA1B—Signaling Pathways—JUN—psoriasis	2.38e-06	1.98e-05	CbGpPWpGaD
Carvedilol—ADRA2C—Signaling Pathways—NFKB1—psoriasis	2.33e-06	1.93e-05	CbGpPWpGaD
Carvedilol—ADRA1B—Signaling Pathways—NFKB1—psoriasis	2.3e-06	1.9e-05	CbGpPWpGaD
Carvedilol—ABCB1—Metabolism—PPARG—psoriasis	2.29e-06	1.9e-05	CbGpPWpGaD
Carvedilol—ADRB1—Signaling Pathways—VEGFA—psoriasis	2.29e-06	1.9e-05	CbGpPWpGaD
Carvedilol—ADRA1A—Signaling Pathways—CXCL8—psoriasis	2.28e-06	1.89e-05	CbGpPWpGaD
Carvedilol—ADRA2B—Signaling Pathways—VEGFA—psoriasis	2.27e-06	1.88e-05	CbGpPWpGaD
Carvedilol—ADRB1—Signaling Pathways—STAT3—psoriasis	2.26e-06	1.88e-05	CbGpPWpGaD
Carvedilol—ADRA2B—Signaling Pathways—STAT3—psoriasis	2.24e-06	1.86e-05	CbGpPWpGaD
Carvedilol—ADRB2—Signaling Pathways—VEGFA—psoriasis	2.24e-06	1.85e-05	CbGpPWpGaD
Carvedilol—ADRB2—Signaling Pathways—STAT3—psoriasis	2.22e-06	1.84e-05	CbGpPWpGaD
Carvedilol—ADRA1A—Signaling by GPCR—IL6—psoriasis	2.17e-06	1.8e-05	CbGpPWpGaD
Carvedilol—CYP2D6—Metabolism—PPARG—psoriasis	2.16e-06	1.79e-05	CbGpPWpGaD
Carvedilol—CYP2C9—Metabolism—PPARG—psoriasis	2.14e-06	1.78e-05	CbGpPWpGaD
Carvedilol—ADRA1A—Signaling Pathways—JUN—psoriasis	2.12e-06	1.76e-05	CbGpPWpGaD
Carvedilol—ADRA2A—Signaling Pathways—CXCL8—psoriasis	2.12e-06	1.75e-05	CbGpPWpGaD
Carvedilol—ADRA2C—Signaling Pathways—VEGFA—psoriasis	2.12e-06	1.75e-05	CbGpPWpGaD
Carvedilol—CYP1A2—Metabolism—APOE—psoriasis	2.1e-06	1.74e-05	CbGpPWpGaD
Carvedilol—ADRA2C—Signaling Pathways—STAT3—psoriasis	2.1e-06	1.74e-05	CbGpPWpGaD
Carvedilol—CYP3A4—Metabolism—CAT—psoriasis	2.09e-06	1.73e-05	CbGpPWpGaD
Carvedilol—ADRA1B—Signaling Pathways—VEGFA—psoriasis	2.08e-06	1.73e-05	CbGpPWpGaD
Carvedilol—ADRA1B—Signaling Pathways—STAT3—psoriasis	2.06e-06	1.71e-05	CbGpPWpGaD
Carvedilol—ADRA1A—Signaling Pathways—NFKB1—psoriasis	2.04e-06	1.69e-05	CbGpPWpGaD
Carvedilol—ADRA2A—Signaling by GPCR—IL6—psoriasis	2.01e-06	1.67e-05	CbGpPWpGaD
Carvedilol—ADRA2A—Signaling Pathways—JUN—psoriasis	1.97e-06	1.63e-05	CbGpPWpGaD
Carvedilol—ADRA1D—Signaling Pathways—TP53—psoriasis	1.9e-06	1.57e-05	CbGpPWpGaD
Carvedilol—ADRA2A—Signaling Pathways—NFKB1—psoriasis	1.89e-06	1.57e-05	CbGpPWpGaD
Carvedilol—ADRA1A—Signaling Pathways—VEGFA—psoriasis	1.85e-06	1.53e-05	CbGpPWpGaD
Carvedilol—ADRA1A—Signaling Pathways—STAT3—psoriasis	1.83e-06	1.52e-05	CbGpPWpGaD
Carvedilol—CYP1A2—Metabolism—PPARG—psoriasis	1.83e-06	1.52e-05	CbGpPWpGaD
Carvedilol—ADRA1D—Signaling Pathways—IL6—psoriasis	1.74e-06	1.44e-05	CbGpPWpGaD
Carvedilol—ADRB1—Signaling Pathways—TP53—psoriasis	1.73e-06	1.43e-05	CbGpPWpGaD
Carvedilol—ADRA2A—Signaling Pathways—VEGFA—psoriasis	1.72e-06	1.42e-05	CbGpPWpGaD
Carvedilol—ADRA2B—Signaling Pathways—TP53—psoriasis	1.71e-06	1.42e-05	CbGpPWpGaD
Carvedilol—ADRA2A—Signaling Pathways—STAT3—psoriasis	1.7e-06	1.41e-05	CbGpPWpGaD
Carvedilol—ADRB2—Signaling Pathways—TP53—psoriasis	1.69e-06	1.4e-05	CbGpPWpGaD
Carvedilol—CYP3A4—Metabolism—APOE—psoriasis	1.62e-06	1.35e-05	CbGpPWpGaD
Carvedilol—ADRA2C—Signaling Pathways—TP53—psoriasis	1.6e-06	1.33e-05	CbGpPWpGaD
Carvedilol—ADRB1—Signaling Pathways—IL6—psoriasis	1.58e-06	1.31e-05	CbGpPWpGaD
Carvedilol—ADRA1B—Signaling Pathways—TP53—psoriasis	1.57e-06	1.3e-05	CbGpPWpGaD
Carvedilol—ADRA2B—Signaling Pathways—IL6—psoriasis	1.57e-06	1.3e-05	CbGpPWpGaD
Carvedilol—ADRB2—Signaling Pathways—IL6—psoriasis	1.55e-06	1.28e-05	CbGpPWpGaD
Carvedilol—ADRA2C—Signaling Pathways—IL6—psoriasis	1.46e-06	1.21e-05	CbGpPWpGaD
Carvedilol—ADRA1B—Signaling Pathways—IL6—psoriasis	1.44e-06	1.19e-05	CbGpPWpGaD
Carvedilol—CYP3A4—Metabolism—PPARG—psoriasis	1.41e-06	1.17e-05	CbGpPWpGaD
Carvedilol—ADRA1A—Signaling Pathways—TP53—psoriasis	1.4e-06	1.16e-05	CbGpPWpGaD
Carvedilol—ADRA2A—Signaling Pathways—TP53—psoriasis	1.3e-06	1.08e-05	CbGpPWpGaD
Carvedilol—ADRA1A—Signaling Pathways—IL6—psoriasis	1.28e-06	1.06e-05	CbGpPWpGaD
Carvedilol—ADRA2A—Signaling Pathways—IL6—psoriasis	1.19e-06	9.86e-06	CbGpPWpGaD
